# LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients

Study · id `cardio:ct-nct02077257` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02077257](<https://clinicaltrials.gov/study/NCT02077257>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02077257

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1060 participants.

## Technical summary

Registry record NCT02077257. Randomized; no masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1060 participants (planned count; ClinicalTrials.gov record NCT02077257, source copy `cardio:ctgov-nct02077257-2014-11-07`, retrieved 2026-10-31)
- Start date: 2014-03 (registry gives no type) (ClinicalTrials.gov record NCT02077257, source copy `cardio:ctgov-nct02077257-2014-11-07`, retrieved 2026-10-31)
- Primary completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT02077257, source copy `cardio:ctgov-nct02077257-2014-11-07`, retrieved 2026-10-31)
- Completion: 2016-05 (anticipated) (ClinicalTrials.gov record NCT02077257, source copy `cardio:ctgov-nct02077257-2014-11-07`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT02077257, source copy `cardio:ctgov-nct02077257-2014-11-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02077257-2014-11-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Rosuvastatin
- Lead sponsor: Committee of Cardio-Cerebral-Vascular Diseases of GSC
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: b3b547232b5051bd21c432bd0fc146b602fa612c0ec0f76190b4a6fc44337b53
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
